Philippe Pouletty is the founder and CEO of Truffle Capital, one of Europe's leading Venture Capital firms. He is a pioneer in the biotech and medical device industries, with over 30 years' experience in France and in the Silicon Valley. He is the inventor of 39 patents, including the second-highest revenue-generating patent in Life Sciences for Stanford University, which earned him induction into the University's prestigious Hall of Fame of Inventors in 2012.

Philippe Pouletty was Chairman of France Biotech from 2001 to 2009 (four terms). He was Vice-Chairman of Europabio for five years. He designed the ""Jeune Entreprise Innovante"" (JEI) status to encourage the development of innovative companies in France.

Dr. Philippe Pouletty is also an entrepreneur: he is founder or co-founder of companies developing cutting-edge technologies in Europe and the United States, including Abivax (BioTech company, largest IPO of French BioTechs on Nasdaq), Carbios (recently honored by Emmanuel Macron in Toulouse: President Emmanuel Macron congratulates Carbios on the 2nd anniversary of France 2030), Vexim (MedTech acquired by Stricker for $200 million), Carmat, Symetis (MedTech acquired by Boston Scientific for $430 million), Affluent Medical (MedTech, listed on the stock exchange), Diaccurate and Caranx Medical.

As a former Paris hospital intern in immunology and hematology, Dr Pouletty holds a doctorate in medicine from the University of Paris VI and a master's degree in immunology and virology from the Institut Pasteur. He was a post-doctoral researcher (1986-1988) at Stanford University.

He is the winner of the 1999 American Liver Foundation Award. Doctor Philippe Pouletty is a Chevalier de la Légion d'Honneur.